ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, the company aims to disrupt the progression of cancer and offer its patients more good days.

Company profile
Ticker
IMGN
Exchange
Website
CEO
Mark Enyedy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
IMMUNOGEN INC
SEC CIK
Corporate docs
Subsidiaries
Hurricane, LLC • ImmunoGen US Holding, Inc. • ImmunoGen Europe Limited • ImmunoGen Switzerland GmbH • ImmunoGen BioPharma (Ireland) Limited • ImmunoGen Securities Corp. ...
IRS number
42726691
IMGN stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
5 May 23
424B5
Prospectus supplement for primary offering
5 May 23
424B5
Prospectus supplement for primary offering
3 May 23
8-K
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
3 May 23
8-K
Entry into a Material Definitive Agreement
2 May 23
S-8
Registration of securities for employees
28 Apr 23
S-8
Registration of securities for employees
28 Apr 23
10-Q
2023 Q1
Quarterly report
28 Apr 23
8-K
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
28 Apr 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
Transcripts
IMGN
Earnings call transcript
2023 Q1
28 Apr 23
IMGN
Earnings call transcript
2022 Q4
1 Mar 23
IMGN
Earnings call transcript
2022 Q3
4 Nov 22
IMGN
Earnings call transcript
2022 Q2
29 Jul 22
IMGN
Earnings call transcript
2022 Q1
6 May 22
IMGN
Earnings call transcript
2021 Q4
25 Feb 22
IMGN
Earnings call transcript
2021 Q3
29 Oct 21
IMGN
Earnings call transcript
2021 Q2
30 Jul 21
IMGN
Earnings call transcript
2021 Q1
10 May 21
IMGN
Earnings call transcript
2020 Q4
12 Feb 21
Latest ownership filings
144
Notice of proposed sale of securities
5 May 23
4
Isabel Kalofonos
2 May 23
3
Isabel Kalofonos
2 May 23
4
Helen M. Thackray
4 Apr 23
4
Stuart A Arbuckle
4 Apr 23
4
Mark Alan Goldberg
4 Apr 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
SC 13G/A
Redmile Group, LLC
14 Feb 23
SC 13G/A
Flynn James E
10 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 201.25 mm | 201.25 mm | 201.25 mm | 201.25 mm | 201.25 mm | 201.25 mm |
Cash burn (monthly) | 24.63 mm | 19.70 mm | 14.13 mm | 20.04 mm | 24.57 mm | 21.84 mm |
Cash used (since last report) | 52.02 mm | 41.61 mm | 29.84 mm | 42.32 mm | 51.90 mm | 46.13 mm |
Cash remaining | 149.23 mm | 159.64 mm | 171.40 mm | 158.93 mm | 149.35 mm | 155.12 mm |
Runway (months of cash) | 6.1 | 8.1 | 12.1 | 7.9 | 6.1 | 7.1 |
Institutional ownership, Q1 2023
93.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 189 |
Opened positions | 23 |
Closed positions | 36 |
Increased positions | 59 |
Reduced positions | 57 |
13F shares | Current |
---|---|
Total value | 775.69 bn |
Total shares | 211.86 mm |
Total puts | 1.41 mm |
Total calls | 4.15 mm |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 21.85 mm | $83.92 bn |
BLK Blackrock | 18.00 mm | $69.11 bn |
Adage Capital Partners GP, L.L.C. | 17.63 mm | $67.71 bn |
STT State Street | 17.08 mm | $65.58 bn |
JHG Janus Henderson | 16.45 mm | $63.19 bn |
Vanguard | 14.97 mm | $57.48 bn |
Wellington Management | 9.86 mm | $37.88 bn |
Redmile | 8.05 mm | $30.90 bn |
Maverick Capital | 7.86 mm | $30.17 bn |
MS Morgan Stanley | 7.32 mm | $28.11 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Apr 23 | Isabel Kalofonos | RSU Common Stock | Grant | Acquire A | No | No | 0 | 47,375 | 0.00 | 47,375 |
28 Apr 23 | Isabel Kalofonos | Stock Option Common Stock | Grant | Acquire A | No | No | 5.39 | 284,250 | 1.53 mm | 284,250 |
31 Mar 23 | Arbuckle Stuart A | Common Stock | Grant | Acquire A | No | No | 3.84 | 3,417 | 13.12 k | 3,417 |
31 Mar 23 | Goldberg Mark Alan | Common Stock | Grant | Acquire A | No | No | 3.84 | 4,394 | 16.87 k | 58,194 |
31 Mar 23 | Thackray Helen M. | Common Stock | Grant | Acquire A | No | No | 3.84 | 1,953 | 7.50 k | 1,953 |
News
AI Boom Wanes In June: Nvidia Falls Under $1T As Benzinga Reviews May's Champions
1 Jun 23
10 Health Care Stocks With Whale Alerts In Today's Session
25 May 23
10 Health Care Stocks With Whale Alerts In Today's Session
8 May 23
Drug Data Sends ImmunoGen (NASDAQ: IMGN) To Multi-Year Highs, Up 150% In Two Days
4 May 23
10 Health Care Stocks Whale Activity In Today's Session
4 May 23
Press releases
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Jun 23
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations
26 May 23
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference
24 May 23
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
9 May 23
ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting
9 May 23